Professional
Added to YB: 2026-05-08
Pitch date: 2026-05-06
DNA [neutral]
Ginkgo Bioworks Holdings, Inc.
+3.2%
current return
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States.
Market Cap
$565.2M
Pitch Price
$10.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.03
P/E
-1.72
EV/Sales
3.42
Sector
Life Sciences Tools and Services
Category
turnaround
Pernas Research More Research Needed On: Ginkgo Bioworks Holdings, Inc.
DNA (more research needed): 'AWS of biology' vision failed post-SPAC boom, down ~99% from peak. Pivoting from COVID biosecurity to autonomous labs & AI bio infrastructure (OpenAI partnership). Burns ~$150M/yr cash. Expert calls suggest viable tech but product-market fit unproven. Large upside if traction materializes given autonomous lab tailwinds.
Read full article (1 min)